Acasti Pharma Return on Tangible Equity 2014-2024 | GRCE
Current and historical return on tangible equity values for Acasti Pharma (GRCE) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Acasti Pharma Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2024-06-30 |
$-0.01B |
$0.01B |
-81.48% |
| 2024-03-31 |
$-0.01B |
$0.01B |
-81.36% |
| 2023-12-31 |
$-0.04B |
$0.02B |
-230.30% |
| 2023-09-30 |
$-0.04B |
$0.02B |
-246.15% |
| 2023-06-30 |
$-0.04B |
$0.02B |
-258.46% |
| 2023-03-31 |
$-0.04B |
$0.02B |
-238.89% |
| 2022-12-31 |
$-0.02B |
$0.01B |
-92.31% |
| 2022-09-30 |
$-0.02B |
$0.02B |
-65.45% |
| 2022-06-30 |
$-0.01B |
$0.02B |
-33.80% |
| 2022-03-31 |
$-0.01B |
$0.03B |
-23.12% |
| 2021-12-31 |
$-0.01B |
$0.05B |
-23.53% |
| 2021-09-30 |
$-0.01B |
$0.05B |
-23.91% |
| 2021-06-30 |
$-0.02B |
$0.05B |
-50.00% |
| 2021-03-31 |
$-0.02B |
$0.06B |
-81.63% |
| 2020-12-31 |
$0.00B |
$0.03B |
23.53% |
| 2020-09-30 |
$-0.01B |
$0.01B |
-150.00% |
| 2020-06-30 |
$-0.02B |
$0.01B |
-8400.00% |
| 2020-03-31 |
$-0.03B |
$0.01B |
1111.11% |
| 2019-12-31 |
$-0.06B |
$-0.01B |
1692.31% |
| 2019-09-30 |
$-0.05B |
$-0.01B |
-1415.38% |
| 2019-06-30 |
$-0.04B |
$-0.00B |
-16800.00% |
| 2019-03-31 |
$-0.04B |
$0.01B |
-7800.00% |
| 2018-12-31 |
$-0.03B |
$0.02B |
3200.00% |
| 2018-09-30 |
$-0.03B |
$-0.02B |
800.00% |
| 2018-06-30 |
$-0.02B |
$-0.00B |
-2100.00% |
| 2018-03-31 |
$-0.02B |
$-0.00B |
-618.18% |
| 2017-12-31 |
$-0.01B |
$0.00B |
-273.68% |
| 2017-09-30 |
$-0.01B |
$0.00B |
-200.00% |
| 2017-06-30 |
$-0.01B |
$0.01B |
-139.13% |
| 2017-02-28 |
$-0.01B |
$0.01B |
-123.08% |
| 2016-11-30 |
$-0.01B |
$0.01B |
-123.08% |
| 2016-05-31 |
$-0.01B |
$0.01B |
-96.00% |
| 2016-03-31 |
$-0.01B |
$0.01B |
-68.97% |
| 2015-12-31 |
$-0.01B |
$0.01B |
-50.00% |
| 2015-09-30 |
$-0.00B |
$0.01B |
-7.41% |
| 2015-06-30 |
$-0.00B |
$0.01B |
-22.22% |
| 2015-03-31 |
$-0.00B |
$0.01B |
-7.02% |
| 2014-12-31 |
$-0.00B |
$0.02B |
-14.29% |
| 2014-06-30 |
$-0.01B |
$0.02B |
-85.71% |
| 2014-03-31 |
$-0.01B |
$0.01B |
-285.71% |
| 2013-12-31 |
$-0.01B |
$0.00B |
-733.33% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$0.033B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
